FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Stock Information for FibroBiologics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About FibroBiologics Inc.

FibroBiologics CEO Issues Letter to Shareholders
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
FibroBiologics Announces Closing of $3 Million Public Offering
FibroBiologics Announces Pricing of $3 Million Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.